For many decades classical anti-tumor therapies included chemotherapy, radiation and
surgery; however, in the last two decades, following the identification of the genomic drivers …

Ferroptosis is an iron-dependent form of programmed cell death, which plays crucial roles in
tumorigenesis, ischemia–reperfusion injury and various human degenerative diseases …

Recent studies have demonstrated that the immunomodulatory drugs (IMiDs) lead to the
degradation of the transcription factors Ikaros and Aiolos. However, why their loss …

Proteasome substrate receptor hRpn13 is a promising anti-cancer target. By integrated in
silico and biophysical screening, we identified a chemical scaffold that binds hRpn13 with …

Multiple myeloma (MM) is a plasma cell neoplasm associated with a broad variety of genetic
lesions. In spite of this genetic heterogeneity, MMs share a characteristic malignant …

Simple Summary Advances in treatment, especially with novel drugs, have dramatically
improved the survival of multiple myeloma (MM) patients recently. However, frequent …

Raised oxidative stress and abnormal redox status are typical features of multiple myeloma
cells, and the identification of the intimate mechanisms that regulate the relationships …

Immunomodulatory imide drugs (IMiDs) are central components of therapy for multiple
myeloma (MM). IMiDs bind cereblon (CRBN), an adaptor for the CUL4‐DDB1‐RBX1 E3 …

A high priority problem in multiple myeloma (MM) management is the development of
resistance to administered therapies, with most myeloma patients facing successively …

Many patients with multiple myeloma (MM) have comorbidities and are treated with PPAR
agonists. Immunomodulatory agents (IMiDs) are the cornerstones for MM therapy. Currently …